Notice of Approval for Rare Pediatric Disease Priority Review Voucher: MRESVIA (Respiratory Syncytial Virus Vaccine)
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The FDA has approved a new product, MRESVIA, a vaccine for Respiratory Syncytial Virus, under its priority review voucher program for rare pediatric diseases. This program helps accelerate the review process for treatments addressing rare conditions affecting children. Pharmaceutical companies with similar products could benefit by gaining faster approval times, thus bringing important therapies to market more quickly.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Introduction of priority review voucher approval for MRESVIA
- Acceleration of review process for treatments of rare pediatric diseases
- Opportunity for faster market entry for similar pharmaceutical products
Obligations
What this law requires
Pharmaceutical companies must apply for priority review vouchers under section 529 of the FD&C Act for products addressing rare pediatric diseases.
FDA must publish notice of the issuance of priority review vouchers for products redeeming such vouchers.
FDA must publish notice of the issuance of priority review vouchers and the approval of products redeeming a priority review voucher.
Companies holding priority review vouchers must ensure their product applications meet the criteria set by the FDA under section 529 of the FD&C Act.
Pharmaceutical companies must ensure that their products meet the criteria for redeeming a priority review voucher as stipulated in the FD&C Act.